Krystal Biotech Inc (KRYS)
170.74
-6.65
(-3.75%)
USD |
NASDAQ |
Nov 15, 16:00
170.76
+0.02
(+0.01%)
After-Hours: 20:00
Krystal Biotech Research and Development Expense (TTM): 51.42M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 51.42M |
| June 30, 2024 | 48.54M |
| March 31, 2024 | 45.10M |
| December 31, 2023 | 46.43M |
| September 30, 2023 | 45.80M |
| June 30, 2023 | 46.69M |
| March 31, 2023 | 45.44M |
| December 31, 2022 | 42.46M |
| September 30, 2022 | 40.73M |
| June 30, 2022 | 35.29M |
| March 31, 2022 | 31.00M |
| December 31, 2021 | 27.88M |
| September 30, 2021 | 24.55M |
| June 30, 2021 | 23.57M |
| March 31, 2021 | 20.61M |
| Date | Value |
|---|---|
| December 31, 2020 | 17.94M |
| September 30, 2020 | 16.61M |
| June 30, 2020 | 15.40M |
| March 31, 2020 | 15.98M |
| December 31, 2019 | 15.62M |
| September 30, 2019 | 14.07M |
| June 30, 2019 | 12.10M |
| March 31, 2019 | 9.408M |
| December 31, 2018 | 7.761M |
| September 30, 2018 | 6.047M |
| June 30, 2018 | 5.488M |
| March 31, 2018 | 4.409M |
| December 31, 2017 | 3.208M |
| September 30, 2017 | 2.522M |
| June 30, 2017 | 1.408M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
15.40M
Minimum
Jun 2020
51.42M
Maximum
Sep 2024
32.85M
Average
33.14M
Median
Research and Development Expense (TTM) Benchmarks
| Bioventus Inc | 13.66M |
| ADMA Biologics Inc | 1.868M |
| Alnylam Pharmaceuticals Inc | 1.098B |
| Amicus Therapeutics Inc | 114.20M |
| Rhythm Pharmaceuticals Inc | 226.68M |